Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frank Russo

Interventional Cardiology Keesler Afb, MS Medical Doctor

NPI 1225369648 CMS profile 967833

301 Fisher St, Keesler Afb, MS 39534

Open in the dashboard

General payments

$7,696

197 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frank Russo of Keesler Afb, MS is reported in the CMS Open Payments database as having received $7,696 across 197 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,140 41
2024 General $678 22
2023 General $2,176 44
2022 General $505 21
2021 General $462 22
2020 General $282 12
2019 General $2,453 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frank Russo
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Frank Russo were reported at $1,140. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Frank Russo Interventional Cardiology median Middle half National median
2019 $2,453 $1,097 $329–$3,048 $163
2020 $282 $473 $161–$1,480 $114
2021 $462 $677 $233–$1,827 $132
2022 $505 $978 $333–$2,724 $149
2023 $2,176 $1,136 $382–$2,986 $160
2024 $678 $1,181 $395–$3,326 $164
2025 $1,140 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,857 81 payments
  2. Boston Scientific Corporation $2,187 34 payments
  3. Medtronic Vascular, Inc. $798 18 payments
  4. Abiomed $420 20 payments
  5. Corindus Inc. $329 3 payments
  6. Atricure, Inc. $154 2 payments
  7. Amgen Inc. $132 9 payments
  8. Abbott Laboratories $127 8 payments
  9. Terumo Medical Corporation $116 1 payment
  10. Surmodics, Inc. $116 1 payment
  11. Other $462 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,912 175 payments
  2. Travel and Lodging $2,784 22 payments
Products named General payments · program years 2019–2025
  1. STINGRAY $1,064 9 payments
  2. AMPLIA MRI QUAD CRT-D SURESCAN $838 11 payments
  3. ROTAPRO $472 6 payments
  4. ATTAIN COMMAND + SUREVALVE $466 24 payments
  5. MICRA Pacemakers $399 9 payments
  6. Micra Pacemakers $331 14 payments
  7. CorPath GRX $329 3 payments
  8. CROSSBOSS $223 3 payments
  9. AVVIGO Guidance System $193 4 payments
  10. Impella $174 7 payments
  11. Other $3,023 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$4,652

Medicare's payments for the services billed

Medicare patients

31

Average age 78

Services billed

53

14 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 61%
Heart failure 58%
Atrial fibrillation 55%
Ischemic heart disease 52%
Arthritis 52%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TYVASO
  • United Therapeutics Corporation $26
$26 — —
Repatha
  • Amgen Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

197 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record